A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: Assessment of efficacy, safety and patient preference

European Journal of Cancer

Volumn 30, Issue 8, 1994, Pages 1083-1088

  Noble, A ^a   Bremer, K ^b   Goedhals, L ^c   Cupissol, D ^d   Dilly, S G ^e  

^a Hôpital Castellucio ^*  (France)

^b Augusta Kranken Anstalt   (Germany)

^c UNIVERSITY OF THE FREE STATE   (South Africa)

^d CENTRE VAL D AURELLE   (France)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

emesis; fractionated chemotherapy; granisetron; ondansetron; patient preference

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; GRANISETRON; IFOSFAMIDE; ONDANSETRON;

ADULT; AGED; ARTICLE; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GRANISETRON; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; ONDANSETRON; VOMITING;

EID: 0028129823     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(94)90461-8     Document Type: Article

References (20)

1. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide
2. Complicated problems of testicular cancer
3. Combination chemotherapy with cis-dichlorodiammineplatinum (II) and adriamycin for testicular cancer refractory to vinblastine plus bleomycin
4. An outline of anti-emetic treatment.
5. Extrapyramidal reactions with high-dose metoclopramide
6. Metoclopramide dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy
7. A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5-day cytostatic therapy
8. The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days
9. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy
10. 3 receptor antagonists the same?
11. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—a randomised study
12. Are granisetron and ondansetron equivalent in the clinic?
13. The two period cross-over clinical trial
14. A log linear model for binary cross-over data
15. The analysis of failure time data in cross over studies
16. The Comparison of Success Rates in Cross-Over Trials in the Presence of an Order Effect
17. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy
18. How should nausea be assessed in patients receiving chemotherapy?